TEST REPORT NO 786381/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**16.10.2025**	
End of analysis	**17.10.2025**	Sample received from the Client
Test report date	**17.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* Copper (Cu) 1) 2) 3) 4) PB-36/ICP ed. 8 of 29.12.2022	mg/dose	0,53 ± 0,13	0,5 (+45%/-20%)	Pass

1) Dose declared by the Client: 3 capsule.

2) Capsule weight declared by the Client: 780,287 mg.

3) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.

4) Client specification.

Authorized by:
ID: 371, Senior Analysis Specialist, Spectrometry Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786388/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections Sample number: 786388/25/GDY
Start of analysis	**16.10.2025**	
End of analysis	**26.11.2025**	Sample received from the Client
Test report date	**26.11.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
# Quercetin 1) 2) HPLC-DAD after extraction				
Quercitin	mg/dose	221,85	180 - 220	Fail

1) Dose declared by the Client: 3 capsules = 2340,861 mg.

2) Client specification.

Test: Quercetin was performed in laboratory PiCA Prüfinstitut Chemische Analytik GmbH Berlin Germany

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786387/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**14.10.2025**	
End of analysis	**15.10.2025**	Sample received from the Client
Test report date	**15.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* Vitamin B2 (ryboflavin) 1) 2) 3) PN-EN 14152:2014-07				
Vitamin B_2 (ryboflavin)	mg/dose	1,32 ± 0,26	1,4	-

1) Dose declared by the Client: 3 capsules.

2) Capsule weight declared by the Client: 780,287 mg.

3) Client specification.

Authorized by:
ID: 758, Analysis Expert, Vitamin and Dioxin Analysis Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786386/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections Sample number: 786386/25/GDY
Start of analysis	**16.10.2025**	
End of analysis	**02.11.2025**	Sample received from the Client
Test report date	**02.11.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
# Folate 1) 2) 3) 4) 5) AOAC 2013.13 / LC-MS/MS				
Methyltetrahydrofolate (5-MTHF)	mg/dose	0,16 ± 0,03	0,3 - 0,56	Fail
Folic acid	mg/dose	< 0,0001	-	-
5-methyltetrahydrofolate calculated as folic acid	mg/dose	0,15	0,16 - 0,3	Fail

1) Dose declared by the Client: 3 capsules.

2) Capsule weight declared by the Client: 780,287 mg.

3) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.

4) The symbol "<" means below the limit of quantification of the analytical method.

5) Client specification.

Test: Folate was performed in laboratory EUROFINS VITAMIN TESTING DENMARK A/S VEJEN Denmark

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

GBAPOLSKA

ANALYTICAL LABORATORIES
microbiology - physicochemistry - sensory

GBA POLSKA Sp. z o.o.
Member of GBA GROUP
ul. Mochtyńska 65, 03-289 Warsaw, Poland

AB 1095

TEST REPORT No: B/0/10/2025/623/F/1/EN

Customer:	AURA HERBALS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ 81-754 Sopot, ul. ul. Grunwaldzka 49
Order No:	B/0/10/2025/623

A - accredited methodology (accreditation no. AB 1095); reference – if the law so provides (the result can be used to assess compliance in the legally regulated area).

Material/product tested:	**Dietary supplements**		
Sample collection address:	80-298 Gdańsk, Botaniczna 12		
Product name:	***Histamin Nadarra, 90 capsules / Histabalance***	**Date*:**	**13 October 2025**
Producer:	*Nadarra GmbH*		
Date of production:	*30/09/2025*		
Lot number:	*HISNAD/30092025*		
Sampling according to: - Samples transported by: Shipping		Received by:	GBA POLSKA employee no: 2729

Sample no:	24959/10/25	Sample condition:	correct	Analysis start date: 13-10-2025	Analysis end date: 22-10-2025

Lab.	Analyzed parameter	Unit	Accred.	Test method	Requirement	Result	U
Ł	Vitamin B12 content (as methylcobalamin)	µg/dose	A	PB-304/LF ed. 2 of 06.03.2025	no requirements	100,5	30.2
Ł	Vitamin B12 content (as methylcobalamin)	µg/100g	A	PB-304/LF ed. 2 of 06.03.2025	no requirements	5075,8	1522.7

Date* - depending on the method of obtaining the sample by GBA POLSKA, it is the date of: collection (when the sample is collected only by a GBA POLSKA employee) or receipt (when the sample is collected from the Customer by a GBA POLSKA employee, is delivered by a courier company or delivered personally by the Customer).
U - expanded measurement uncertainty at the level of confidence app. 95% and the coverage factor k=2, does not take into account the sampling uncertainty, except when indicated in the remarks. Measurement uncertainty is provided when it is important for the reliability of test results or compliance with requirements/specifications and at the request of the Customer. The "test results" lower or higher than the measuring ranges of the methods are presented as "<value of the lower limit of the measuring range " or "> value of the upper limit of the measuring range", respectively. These values provide information about the research results. If expanded uncertainties are given with these test results, they apply to the lower or upper limit of the measuring range of the method.
The results refer only to the tested samples (sampled or received - in accordance with the information presented in the Test Report).
The information in italics included in the Test Report was provided by the Customer. The laboratory is not responsible for this information. The laboratory is not resposible for the method of sampling and the representativeness of the samples provided by the Customer for testing.
The Test Report without the written approval of the Laboratory shall not be reproduced except in full.
The Laboratory does not store the samples after testing, unless otherwise agreed with the Customer.
Place of performance of the tests ("Lab."): Ł - Łajski, ul. Kościelna 2a, 05-119 Legionowo, L - ul. Doświadczalna 50a, 20-280 Lublin, M - ul. Fabryczna 7, 41-404 Mysłowice, P – ul. Kazimierza Tymienieckiego 34, 60-681 Poznań, W – ul. Ząbkowska 18, 03-735 Warszawa, PS - in situ measurement.

NOTE: Original Test Report is issued in electronic form with the *.pdf extension, signed with a qualified electronic signature. Therefore, all prints, unless certified as true copies, are copies.

Remarks:
Dose=3 capsules (capsule weight 780.287 mg)-in accordance with the information from the Client.

Created on:	**Authorized result:**	**Authorized Test report:**	
06-11-2025	GBA POLSKA employee no: 2705	Documentation specialist for the food testing industry GBA POLSKA employee no: 2942	**Signed with a qualified electronic signature**

Report prepared in a single copy **Original of PDF: Customer, copy of PDF to: Laboratory archive**

The end of the Test Report

TEST REPORT NO 786384/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**14.10.2025**	
End of analysis	**17.10.2025**	Sample received from the Client
Test report date	**17.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* Vitamin C 1) 2) 3) 4) PB-135/HPLC ed. II of 15.09.2015	mg/dose	488 ± 38	500	-

1) Dose declared by the Client: 3 capsules.

2) Capsule weight declared by the Client: 780,287 mg.

3) Undefined threshold values.

4) Client specification.

Authorized by:
ID: 758, Analysis Expert, Sekcja Autoryzacji

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786382/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**14.10.2025**	
End of analysis	**28.10.2025**	Sample received from the Client
Test report date	**28.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* Vitamin B6 1) 2) 3) 4) PN-EN 14164:2014-08				
Vitamin B_6 (pyridoxine hydrochloride)	mg/dose	3,76 ± 0,75	-	-
Vitamin B6 (pyridoxine)	mg/dose	3,09 ± 0,62	10 (+50%/-20%)	Fail

1) Dose declared by the Client: 3 capsules.

2) Capsule weight declared by the Client: 780,287 mg.

3) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.

4) Client specification.

Authorized by:
ID: 758, Analysis Expert, Sekcja Autoryzacji

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786383/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**16.10.2025**	
End of analysis	**16.10.2025**	Sample received from the Client
Test report date	**16.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* Zinc (Zn) 1) 2) 3) 4) PB-36/ICP ed. 8 of 29.12.2022	mg/dose	10,6 ± 2,7	10	-

1) Dose declared by the Client: 3 capsules.

2) Capsule weight declared by the Client: 780,287 mg.

3) Undefined threshold values.

4) Client specification.

Authorized by:
ID: 295, Analysis Expert, Spectrometry Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
# Test performed by external provider

THE END OF THE REPORT

TEST REPORT NO 786385/25/GDY

Client **NÀDARRA GmbH** Harvestehuder Weg 48 20149 Hamburg	Sample (according to declaration of Client) Sample description: Histamin Nadarra, 90 capsules / Histabalance Batch: HISNAD/30092025 Production date: 30.09.2025 Expiry date: 30.09.2027

Sample reception date:	**13.10.2025**	Sample status: no objections
Start of analysis	**15.10.2025**	
End of analysis	**27.10.2025**	Sample received from the Client
Test report date	**27.10.2025**	

Test **Method**	**Unit**	**Result**	**Criteria**	**Statement of conformity**
* # Amino acids - composition 1) 2) 3) 4) ISO 13903:2005 (IC-UV)				
Alanine	mg/dose	< 0,351	-	-
Arginine	mg/dose	< 0,234	-	-
Aspartic acid	mg/dose	< 0,398	-	-
Glutamic acid	mg/dose	506 ± 71	-	-
Glycine	mg/dose	25,7 ± 3,6	-	-
Histidine	mg/dose	< 0,468	-	-
Hydroxyproline 5)	mg/dose	< 4,68	-	-
Isoleucine	mg/dose	< 0,819	-	-
Leucine 5)	mg/dose	27,6 ± 3,9	30	-
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]